SCHEMBL4298747

SCHEMBL4298747

S=C(Nc1ccccn1)Oc1ccccn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.53
NPC1 O15118 6/20 0.53
NPSR1 Q6W5P4 5/20 0.53
ALDH1A1 P00352 5/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
PKM P14618 3/20 0.53
GAA P10253 3/20 0.53
KDM4E B2RXH2 1/20 0.53
TP53 P04637 1/20 0.53
MAPT P10636 1/20 0.53
HPGD P15428 1/20 0.53
NFKB1 P19838 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53
HSD17B10 Q99714 1/20 0.53
ATG4B Q9Y4P1 1/20 0.53
ALOX12 P18054 4/20 0.48
KMT2A Q03164 2/20 0.47
POLB P06746 1/20 0.47
MIF P14174 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20448089 0.79 RAB9A (0.59) RAB9ANPC1ALDH1A1SMN1; SMN2PKM
SCHEMBL2682040 0.75 RAB9A (0.71) RAB9ANPC1NPSR1ALDH1A1SMN1; SMN2
SCHEMBL435144 0.75 KDM4E (0.44) RAB9ANPC1NPSR1ALDH1A1SMN1; SMN2
SCHEMBL11327867 0.75 RAB9A (0.66) RAB9ANPC1NPSR1ALDH1A1SMN1; SMN2
SCHEMBL31734268 0.75 KDM4E (0.44) RAB9ANPC1NPSR1ALDH1A1SMN1; SMN2
SCHEMBL8691430 0.75 RAB9A (0.52) RAB9ANPC1NPSR1ALDH1A1SMN1; SMN2
Methyl Alcohol SCHEMBL4399392 0.75 RAB9A (0.52) RAB9ANPC1NPSR1ALDH1A1SMN1; SMN2
SCHEMBL8916188 0.74 RAB9A (0.63) RAB9ANPC1NPSR1ALDH1A1SMN1; SMN2
SCHEMBL670301 0.74 KDM4E (0.42) RAB9ANPC1NPSR1ALDH1A1SMN1; SMN2
SCHEMBL3043860 0.73 RAB9A (0.35) RAB9ANPC1NPSR1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270391-A1 THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY KIRIN PHARMA KABUSHIKI KAISHA (JP) 2009-10-29 US disclosed
EP-1870414-A1 THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING C-MET AUTOPHOSPHORYLATION INHIBITING POTENCY Kirin Pharma Kabushiki Kaisha (JP) 2007-12-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270391-A1 THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY MET, ABL1, RET RAB9A 2323/4885NPC1 3380/4885NPSR1 1415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.